Australia's largest stock trading and investment forum Australia's #1 stock forum

IHL

Click for more information

0.00%

4.1¢ incannex healthcare limited

General discussion, page-18333

First 18333 Last

Share
Profile

Follow
Grogger

164 Posts.

48

16/11/23

12:10

Post #: 70936768
Share

Originally posted by Flectional: ↑

I am constantly amazed and left speechless at the drivel posted by some here - really pretty much don't bother replying anymore

BUT Jim jam what are you talking about exactly?

the products being developed here for indications of unmet need globally have progressed and developed substantially since the high times of 70c SP back when the market was awash with coin due to QE and economic market stimulation
It now sits in a retrace aligned to the QT that has occurred in markets since 21/22 - Australia has declining productivity and a marginal increase in real wages leaving investors with declining cash at hand and driving the current inflationary environment which continues north making the situation even more of a squeeze -

There is no bottom on the SP = some of the clowns here are just starting to realise this simple fact - that is truely remarkable because this is a biotech / pharmaceutical start up and real SP appreciation will not occur until human data starts hitting the read out analysis on the back of phase III trials.

Anyone with an ounce of intelligence understands this very simple reality.
whether the SP is 70c or 1c is irrelevant UNTIL that data starts flowing. - OR here once Clarion starts treating patients ...not the authorisation to move from the TGA ...that will have zero SP effect - treating patients is the key to pharmaceutical companies - remember that if in the future you are invested in opther such start ups devloping drug candidates for commercialisation .....human data that is safe and efficacious drives the business....then follows revenue - nothing else
SO - this value at 5,2c is a mispriced opportunity to buy.

that is the gap between asset value here and what you are being asked to pay to have a piece of that action and that represents value on that basis - why buy in if that is not the case.

It was cheap at 70c and that's why it was being bought - supply and demand
its also why there are buyers at 5.2c ....mispriced opportunity - again supply and demand

terms such as rampers / hopium / and those blamers who use them frequently when posting the unrealistic gripes they have about the paper losses they hold is farcical ..

I buy mispriced opportunities - nothing more nothing less - zero here has changed and the company drives its strategic end game toward the goals it continually outlines to the market and the holders here..it remains a mispriced value opportunity - US coin will see it pretty clearly imo

pretty simple really .-
the Ndaq will offer volume and liquidity that is not available on the ASX - again simple strategic opportunity leveraged by the bod and shareholders to realise that opportunity for growth WHEN that human data out the back of those phase III trials drops.

see you on the NDaq. - ignore the noise

Expand

“pretty simple really .- the Ndaq will offer volume and liquidity that is not available on the ASX - again simple strategic opportunity leveraged by the bod and shareholders to realise that opportunity for growth WHEN that human data out the back of those phase III trials drops.”

huh?

IHL has plenty of volume and liquidity on the ASX, in fact it’s likely to have liquidity less on the NDQ given holders will remain predominately Australians on a different time zone, and a share consolidation actually restricts volume.

NDQ will offer access to more capital avenues. That’s what management want. That is what this is about.

IHL Price at posting: 5.2¢ Sentiment: None Disclosure: Not Held
7 Upvote

1 Great analysis

Reply

Top Stories

HotCopper Highlights: Your most watched and most discussed stocks this week

Trump Victory Sends Bitcoin Surging Above $75K – Is $100K Next?

Trump is President Again: What Does This Mean for Crypto?

IMU

Imugene kicks off Australian trial for blood cancer treatment

MMI

Metro Mining inks bauxite offtake contracts into 2026 with Chinese m

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

UBI

Universal Biosensors flat despite fresh deal with US medical product distributor

Week 45 Wrap: Combat sports usher in Trump 2.0 – or is it male insecurity?; RBA boring; Propane suggests China alive

FG1

Flynn Gold reaches milestone exploration target for Golden Ridge

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

There are more pages in this discussion • 2,127 more messages in this thread...

First 18333 Last

Add IHL (ASX) to my watchlist